What are The Oncology Institute, Inc.'s total assets?

The Oncology Institute, Inc. (TOI) holds $168.2M in total assets, up 2.6% year over year.

How much debt does The Oncology Institute, Inc. have?

The Oncology Institute, Inc. carries $104.9M in total debt against -$16.3M of shareholders' equity, a debt-to-equity ratio of 20.21.

How much cash does The Oncology Institute, Inc. have?

The Oncology Institute, Inc. holds $30.3M in cash and equivalents.

Can The Oncology Institute, Inc. cover its short-term obligations?

Its current ratio is 1.47 — current assets exceed current liabilities.

Where does The Oncology Institute, Inc.'s balance sheet data come from?

Every line is extracted from The Oncology Institute, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

The Oncology Institute, Inc. TOI Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$33.57M-32.4%	$49.67M+48.3%	$33.49M+139%	$14.01M-87.8%
Accounts receivable, net	$223.62M+3.7%	$215.61M+17.7%	$183.15M+43.0%	$128.1M+429%
Inventories	$63.85M+48.4%	$43.02M-10.9%	$48.27M+35.5%	$35.63M+358%
Prepaid expenses and other current assets	$2.99M-25.9%	$4.03M-0.5%	$4.05M-41.5%	$6.92M-38.2%
Total current assets	$112.75M+0.3%	$112.42M-21.7%	$143.49M+10.0%	$130.42M-15.3%
Property and equipment, net	$10.68M-10.1%	$11.89M+9.2%	$10.88M+27.3%	$8.55M+104%
Accumulated depreciation	$10.93M+56.7%	$6.97M+12.8%	$6.18M+76.3%	$3.51M+76.7%
Operating lease right-of-use assets	2,237,400,000%-340,800,000%	2,578,200,000%-338,700,000%	2,916,900,000%+467,500,000%	2,449,400,000%—
Goodwill	$7.23M0.0%	$7.23M0.0%	$7.23M-66.2%	$21.42M-19.6%
Intangible assets, net	$11.02M-25.6%	$14.81M-17.3%	$17.9M-0.3%	$17.96M-1.6%
Other non-current assets	$606K+2.9%	$589K+5.0%	$561K+17.6%	$477K+49.1%
Total assets	$164.66M-4.7%	$172.72M-17.5%	$209.24M-20.0%	$261.67M+28.6%
Accounts payable	$43.17M+77.5%	$24.32M+68.6%	$14.43M+54.0%	$9.37M-39.8%
Accrued expenses	$7.09M-66.4%	$21.09M+50.7%	$14M-4.1%	$14.6M+4.8%
Current portion of long-term debt	——	——	——	$0-100%
Operating lease liabilities, current	$7.16M+5.3%	$6.8M+6.8%	$6.36M+15.7%	$5.5M—
Finance Lease Liability, Current	$36K-2.7%	$37K-7.5%	$40K-44.4%	$72K—
Contract liabilities	$0-100%	$2.35M—	$0-100%	$545K+148%
Accrued interest	$878K-22.7%	$1.14M+1.1%	$1.12M+2.2%	$1.1M—
Other current liabilities	$4.31M-18.9%	$5.31M+47.5%	$3.6M+11.3%	$3.23M+8.9%
Claims and insurance accruals	$2.28M+196%	$770K-23.2%	$1M-66.7%	$3.01M-39.9%
Total current liabilities	$70.96M+35.9%	$52.22M+50.1%	$34.79M+17.1%	$29.72M-0.3%
Long-term debt	$77.4M-16.9%	$93.13M+7.3%	$86.83M+7.7%	$80.62M—
Operating lease liabilities, non-current	$19.13M-17.6%	$23.22M-12.3%	$26.49M+20.1%	$22.06M—
Finance Lease Liabilities (Total)	$64K-36.6%	$101K-27.9%	$140K-41.9%	$241K—
Operating Lease Liabilities (Total)	$26.29M-12.4%	$30.02M-8.6%	$32.85M+19.2%	$27.56M—
Finance lease liabilities	$28K-56.3%	$64K-36.0%	$100K-40.8%	$169K—
Other non-current liabilities	$28K-77.6%	$125K-65.8%	$365K-57.9%	$868K-87.4%
Total liabilities	$180.38M+6.7%	$169.13M+11.1%	$152.22M+9.9%	$138.49M+39.5%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	500M+6,249,900%	8K0.0%	8K+14.3%	7K0.0%
Additional paid-in capital	$256.71M+19.2%	$215.41M+5.5%	$204.19M+9.6%	$186.25M+11.3%
Retained earnings	-$271.42M-28.7%	-$210.81M-44.2%	-$146.15M-132%	-$63.08M+0.2%
Treasury stock	$1.02M0.0%	$1.02M0.0%	$1.02M—	$0—
Total stockholders' equity	-$15.72M-538%	$3.59M-93.7%	$57.03M-53.7%	$123.18M+18.3%
Total liabilities and stockholders' equity	$164.66M-4.7%	$172.72M-17.5%	$209.24M-20.0%	$261.67M+28.6%
Allowance for Doubtful Accounts	$0—	$0—	$0—	$0—
Allowance for Doubtful Accounts Receivable (Current)	$0—	$0—	$0—	$0—
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$322K-6.9%	$346K-37.2%	$551K-10.7%	$617K-50.1%
Other Receivables	$322K-6.9%	$346K-37.2%	$551K-10.7%	$617K-50.1%
Deferred Tax Assets and Other Non-Current Assets	$606K+2.9%	$589K+5.0%	$561K+17.6%	$477K+49.1%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$29.77M-7.1%	$32.03M0.0%	$32.03M+10.2%	$29.08M+9.8%
Net Investment in Lease	$22.37M-13.2%	$25.78M-11.6%	$29.17M+19.1%	$24.49M—
Intangible assets — net	$11.02M-25.6%	$14.81M-17.3%	$17.9M-0.3%	$17.96M-1.6%
Other intangible assets—net	$11.02M-25.6%	$14.81M-17.3%	$17.9M-0.3%	$17.96M-1.6%
Operating lease right-of-use assets	$22.37M-13.2%	$25.78M-11.6%	$29.17M+19.1%	$24.49M—
Other non-current assets	$606K+2.9%	$589K+5.0%	$561K+17.6%	$477K+49.1%
Operating Lease Right-of-Use Assets in Other Assets	$22.37M-13.2%	$25.78M-11.6%	$29.17M+19.1%	$24.49M—
Software and Technology Licenses, Net	$606K+2.9%	$589K+5.0%	$561K+17.6%	$477K+49.1%
Accrued Manufacturing Costs	$7.09M+1.7%	$6.98M+26.4%	$5.52M+3.9%	$5.31M+59.7%
Other Commercial Liabilities	$20.64M-2.2%	$21.09M+50.7%	$14M-4.1%	$14.6M+4.8%
Accrued Liabilities, Current	$20.64M-2.2%	$21.09M+50.7%	$14M-4.1%	$14.6M+4.8%
Compensation and benefits	$7.09M+1.7%	$6.98M+26.4%	$5.52M+3.9%	$5.31M+59.7%
Other accrued liabilities	$20.64M-2.2%	$21.09M+50.7%	$14M-4.1%	$14.6M+4.8%
Derivative Liabilities - Fair Value	$12.59M+3,170%	$385K-87.5%	$3.08M-22.2%	$3.96M—
Finance Lease Liability Payment Due	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Debt Maturity - 2024	——	——	——	——
Derivative Liabilities (Non-Current)	$12.59M+3,170%	$385K-87.5%	$3.08M-22.2%	$3.96M—
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Total debt	$103.75M-15.8%	$123.25M+2.9%	$119.82M+10.5%	$108.42M+59,146%
Total Carrying Value of Debt	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	100.6M+29.9%	77.5M+2.1%	75.9M+3.6%	73.3M0.0%
Common Stock Shares Outstanding	——	——	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	193.5K+17.2%	165K0.0%	165K0.0%	165K+0.9%
Convertible Preferred Stock Outstanding Shares	193.5K+17.2%	165K0.0%	165K0.0%	165K+0.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$10K+25.0%	$8K0.0%	$8K+14.3%	$7K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——
Preferred Stock Liquidation Preference Value	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	4M-46.3%	7.5M-12.2%	8.5M+5.9%	8M+16.3%
Weighted Average Exercise Price of Outstanding Options	$2.23+33.5%	$1.67-4.0%	$1.74-18.7%	$2.14+140%
Number of Countries of Operation	——	——	——	——
Accounts Payable Interest Bearing Interest Rate	7.5%-0.5%	8%-0.8%	8.8%—	——
Accounts receivable, remaining amount	——	——	$48.34M+21.4%	$39.82M—
Accrued capitated leakage	$1.68M+43.3%	$1.17M—	——	——
Accrued Insurance Current And Noncurrent	$794K+3.1%	$770K-23.2%	$1M—	——
Accrued Sub-Capitation	$1.85M—	——	——	——
Accounts Receivable, Allowance for Credit Loss	$0—	$0—	——	——
Allowance for doubtful accounts	$0—	$0—	$0—	$0—
Deferred acquisition and contingent consideration	$125K-30.6%	$180K-91.8%	$2.21M+175%	$802K-66.0%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M0.0%	$500M0.0%
Common stock, shares issued (in shares)	$100.6M+29.9%	$77.47M+2.1%	$75.88M+3.6%	$73.27M0.0%
Common Stock, Shares, Outstanding	$98.86M+30.5%	$75.74M+2.1%	$74.15M+1.2%	$73.27M0.0%
Contract with Customer, Asset, after Allowance for Credit Loss	$0—	$0—	$0—	$0—
Contract with Customer, Liability	$0-100%	$2.35M—	$0-100%	$545K+148%
Long-term debt, gross	——	——	——	——
Derivative Liability, Noncurrent	$12.59M+3,170%	$385K-87.5%	$3.08M-22.2%	$3.96M—
Derivative warrant liabilities	$264K+1,453%	$17K-97.3%	$636K+81.7%	$350K-84.0%
Current maturities of long-term debt	$36K-2.7%	$37K-7.5%	$40K-44.4%	$72K—
Finance Lease Liability Payments Due	——	——	——	——
2027	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——
Thereafter	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——
Thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$18.75M+8.9%	$17.22M+21.9%	$14.13M+27.1%	$11.12M+35.0%
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Gross Carrying Amount	$29.77M-7.1%	$32.03M0.0%	$32.03M+10.2%	$29.08M+9.8%
Directors and officers insurance premiums	$794K—	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Number of equity offerings	——	——	——	——
Number Of States In Which Entity Operates	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——
Other	$4.31M-18.9%	$5.31M+47.5%	$3.6M+11.3%	$3.23M+8.9%
Preferred Stock Liquidation Preference	——	——	——	——
Maximum percent of common stock allowed	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$193.51K+17.2%	$165.05K0.0%	$165.05K0.0%	$165.05K+0.9%
Preferred Stock, Shares Outstanding	$193.51K+17.2%	$165.05K0.0%	$165.05K0.0%	$165.05K+0.9%
Repayments on advances	$1.63M-49.0%	$3.2M—	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$4.02M-46.3%	$7.49M-12.2%	$8.53M+5.9%	$8.05M+16.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$2.23+33.5%	$1.67-4.0%	$1.74-18.7%	$2.14+140%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——
Treasury stock, shares (in shares)	$1.73M0.0%	$1.73M0.0%	$1.73M—	$0—
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——
Weighted-Average Discount Rate	——	——	——	——
Weighted-Average Discount Rate - Finance Leases	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about The Oncology Institute, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are The Oncology Institute, Inc.'s total assets?: The Oncology Institute, Inc. (TOI) holds $168.2M in total assets, up 2.6% year over year.
How much debt does The Oncology Institute, Inc. have?: The Oncology Institute, Inc. carries $104.9M in total debt against -$16.3M of shareholders' equity, a debt-to-equity ratio of 20.21.
How much cash does The Oncology Institute, Inc. have?: The Oncology Institute, Inc. holds $30.3M in cash and equivalents.
Can The Oncology Institute, Inc. cover its short-term obligations?: Its current ratio is 1.47 — current assets exceed current liabilities.
Where does The Oncology Institute, Inc.'s balance sheet data come from?: Every line is extracted from The Oncology Institute, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.